Is Egrifta (Tesamorelin) Legal in Michigan?
HealthRX.com
Egrifta is FDA-approved; Michigan rules are not covered here
Key numbers
- 2 mgEgrifta SV vial strength, one of the two current FDA-labeled versionsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 11.6 mgEgrifta WR vial strength, the other current FDA-labeled versionSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 5%Share of tesamorelin patients reaching HbA1c 6.5% or higher by week 26 (glucose intolerance)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Tesamorelin
At a glance
- Federal status / FDA-approved prescription drug, application BLA 022505, first approved November 10, 2010 [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
- Current products / Egrifta SV 2 mg vial and Egrifta WR 11.6 mg vial, once-daily subcutaneous injection [2][3]
- Weight loss / Label states a weight-neutral effect and no weight-loss indication [2]
- Compounded tesamorelin / Not FDA-approved; FDA has made no category-based statement about compounding it [4][5][6][7]
- Sport / WADA prohibits tesamorelin at all times, in and out of competition [8][9]
What the federal approval actually covers
Egrifta (tesamorelin acetate) was first approved on November 10, 2010, under application BLA 022505, and the FDA approval record lists it as a prescription product [1]. The labels for the two current versions, Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), each give a single indication: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy [2][3].
Both labels set limits on that use. Long-term cardiovascular safety has not been established, prescribers are told to weigh the risk and benefit of continuing in patients who have not had a reduction in visceral adipose tissue, and tesamorelin is not indicated for weight loss management because it has a weight-neutral effect [2][3]. Use in people without HIV lipodystrophy falls outside the label [2].
Questions worth asking
Compounded tesamorelin: what FDA has said
FDA keeps a list of bulk drug substances that may present significant safety risks when compounded. Tesamorelin is not on that list, which is dated April 22, 2026 [4]. It also appears in no category of FDA's lists for state-licensed pharmacies and physicians (updated May 14, 2026) or for outsourcing facilities (updated March 21, 2025) [5][6]. So FDA has made no category-based statement about compounding tesamorelin, and the substance is already a component of an FDA-approved drug, Egrifta [4][5][6].
Tesamorelin is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [7][10].
A compounded version of tesamorelin is not an FDA-approved drug. FDA does not review the safety, effectiveness or quality of compounded drugs before they are marketed [7].
Label safety requirements
The Egrifta SV label says to monitor IGF-1 and to consider stopping if levels stay elevated, for example above 3 standard deviation scores, particularly when the effect on fat is not robust [2]. It also lists glucose intolerance: 5% of tesamorelin patients versus 1% of placebo patients reached an HbA1c of 6.5% or higher by week 26 [2]. The label lists four contraindications: disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [2].
Athletes: tesamorelin is prohibited in sport
WADA's Prohibited List names tesamorelin in section S2.2.4 under growth hormone releasing factors, prohibits it at all times in and out of competition, and treats S2 substances as non-Specified Substances [8]. It is on the 2026 List (in force since January 1, 2026) and remains on the 2027 List [8][9].
Frequently asked questions
Is Egrifta (tesamorelin) legal in Michigan?
Can tesamorelin be compounded?
Is tesamorelin approved for weight loss?
Can an athlete use tesamorelin?
References
Show all 10 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Official web page.